Racial differences in HLA-class II associations with hepatitis C virus outcomes

Every CRO out there will tell you they’re site-centric, and on pitch decks, they use the right

You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team,

ICH E6(R3) is here, and with it, clinical teams are bracing for the impacts. Biotechs are being